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Abstract
Background: The present study was designed to investigate the antibacterial activities of the methanol extracts
from different parts of Beilschmedia acuta Kosterm (Lauraceae), Clausena anisata (Willd) Hook (Rutaceae),
Newbouldia laevis Seem (Bignoniaceae) and Polyscias fulva (Hiern) Harms (Araliaceae) as well as their synergistic
effects with antibiotics against a panel of Gram-negative bacteria, including multi-drug resistant (MDR) phenotypes
expressing active efflux pumps.
Methods: Broth microdilution method was used to determine the minimum inhibitory concentrations (MICs) and
the minimum bactericidal concentrations (MBCs) of the extracts, as well as those of antibiotics in association with
the most active ones, B. acuta, N. laevis and P. fulva.
Results: MIC values obtained indicate that extracts from the bark of B. acuta were active on all the 26 tested
Gram-negative bacteria, with MICs ranging from values below 8 to 256 μg/mL. Other samples displayed
selective activities, their inhibitory effects being observed on 9 (34.62 %) of the 26 bacterial strains for N.
laevis leaves extract, 6 (23.10 %) for both C. anisata leaves and roots extracts, 7 (26.9 %) and 4 (15.4 %) for
leaves and roots extracts of P. fulva respectively. Extract from B. actua bark displayed the best antibacterial
activity with MIC values below 100 μg/mL against 16 (61.5 %) of the 26 tested microorganisms. The lowest
MIC values (below 8 μg/mL) were obtained with this extract against Escherichia coli W3110 and Klebsiella
pneumoniae ATCC11296. The MIC values of this extract were lower than those of ciprofloxacin against E. coli
W3110, Enterobacter aerogenes ATCC13048, CM64 and Providencia stuartii NAE16. At MIC/2, the best
percentages of synergistic effects (100 %), were obtained with B. acuta bark extract and tetracycline (TET) as
well as with P. fulva leaves extract and TET and kanamycin (KAN).
Conclusion: The overall results of the present study provide information for the possible use of the studied
plants and mostly Beilschmedia acuta in the control of bacterial infections including MDR phenotypes.
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Background
Fighting multi-drug resistant (MDR) Gram-negative
(MDRGN) bacteria remains a challenging issue
worldwide. Microbial infections involving MDRGN
bacteria constitute a major public health problem in
developing countries [1] where the high cost of anti-
biotics makes them unaffordable to the majority of
the population. Clinically, the continuous emergence
of MDRGN bacteria drastically reduced the efficacy
of antibiotic arsenal and, consequently, increased the
frequency of therapeutic failure [2]. Therefore, the
discovery of new antimicrobial agents is still relevant
nowadays. Also, the shortcomings of drugs available
today and scarcity of novel antibiotics propel the
discovery of new chemotherapeutic agents from me-
dicinal plants [3]. Approximately 60 % of the world
population still relies on medicinal plants for their
primary healthcare [4]. Medicinal plants have been
used as a source of remedies since ancient times in
Africa. In addition, promising new concepts such as
the efflux pump inhibitors [5, 6], and synergy be-
tween antibiotics and phytochemicals are now being
developed. The ability of several African medicinal
plants to inhibit the growth of MDRGN bacteria, as
well as their ability to potentiate the activity of com-
monly used antibiotics was previously reported.
Some of these plants include Dorstenia psilurus,
Dichrostachys glomerata and Beilschmiedia cinnamo-
mea [7–9].
In our continuous search of plant extracts with
antibiotic-potentiating activity to combat MDR bacteria,
the present work was designed to investigate the anti-
bacterial activity of four Cameroonian medicinal plants
used traditionally in the treatment of bacterial infections,
namely Beilschmiedia acuta Kosterm (Lauraceae), Clau-
sena anisata (Willd) Hook (Rutaceae), Newbouldia lae-
vis Seem (Bignoniaceae) and Polyscias fulva (Hiern)
Harms (Araliaceae), against MDRGN expressing active
efflux via the Resistance-Nodulation Cell Division
(RND)-type pumps. In the treatment of infectious dis-
eases, Beilschmiedia acuta is traditionally used for
gastrointestinal infections [10], Clausena anisata for
fungal, bacterial and viral infections, Newbouldia laevis
for bacterial and fungal infections [11–14], dysentery,
worms, malaria, dental caries and diarrhea [15] and
Polyscias fulva for venereal infections [16, 17].
Methods
Plant material and extraction
All medicinal plants used in the present work were
collected in different areas of Cameroon between January
and April 2012. The plants were identified at the National
Herbarium (Yaounde, Cameroon), where voucher speci-
mens were deposited under the reference numbers
(Table 1). Air-dried and powdered plant material was
weighed (300 g) and soaked in 1 L of methanol (MeOH)
for 48 h at room temperature. The filtrate obtained
through Whatman filter paper No.1 was concentrated
under reduced pressure in a vacuum to obtain the crude
extract. All crude extracts were kept at 4 °C until further
use.
Antimicrobial assays
Chemicals for antimicrobial assays
Tetracycline (TET), ciprofloxacine (CIP), chlorampheni-
col (CHL), ampicillin (AMP) and kanamycin (KAN)
(Sigma-Aldrich, St Quentin Fallavier, France) were used
as reference antibiotics (RA). p-Iodonitrotetrazolium
chloride (INT, Sigma-Aldrich) was used as a microbial
growth indicator [18, 19].
Microbial strains and culture media
The studied microorganisms included sensitive and re-
sistant strains of Pseudomonas aeruginosa, Klebsiella
pneumoniae, Enterobacter aerogenes, Escherichia coli ob-
tained from the American Type Culture Collection
(ATCC). Their bacterial features are summarized in
Table 2. Nutrient agar was used to activate the tested
Gram-negative bacteria [20].
INT colorimetric assay for MIC and MBC determinations
The MIC determination on the tested bacteria was con-
ducted using rapid p-iodonitrotetrazolium chloride (INT)
colorimetric assay according to described methods [18]
with some modifications [21, 22]. The test samples and
RA were first dissolved in DMSO/Mueller Hinton Broth
(MHB). The final concentration of DMSO was lower than
2.5 % and does not affect the microbial growth [23, 24].
The solution obtained was then added to Mueller Hinton
Broth, and serially diluted two fold (in a 96- wells
microplate). One hundred microlitre (100 μL) of inoculum
1.5 x 106 CFU/mL prepared in appropriate broth was then
added [21, 22]. The plates were covered with a sterile plate
sealer, then agitated to mix the contents of the wells using
a plate shaker and incubated at 37 °C for 18 h. The assay
was repeated thrice. Wells containing adequate broth,
100 μL of inoculum and DMSO to a final concentration
of 2.5 % served as negative control. The MIC of samples
was detected after 18 h incubation at 37 °C, following
addition (40 μL) of 0.2 mg/mL of INT and incubation at
37 °C for 30 min. Viable bacteria reduced the yellow dye
to pink. The MIC was defined as the sample concentra-
tion that prevented the color change of the medium and
exhibited complete inhibition of microbial growth [18].
The MBC was determined by adding 50 μL aliquots of the
preparations, which did not show any growth after incu-
bation during MIC assays, to 150 μL of adequate broth.
These preparations were incubated at 37 °C for 48 h. The
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breast, glioblastoma, colon and









malaria, fungal, bacterial and viral infections,
inflammation, heart and mental disorders,
constipation, convulsions, impotence and
sterility [43–46]
Essential oils (sabinene, β-pinene,
pulegone, 1,8 -cineole, estragole,
[42]; carbazole alkaloids, coumarins,
limonoids [46, 47].
Antimicrobial: Essential oil active





and barks (19.35 %)
Melon, Littoral region of
Cameroon
(04°33'53"N 09°38'04"E)
Cancers, spasms, infectious diseases, male
infertility and diabetes [11, 12], coagulant
or anti-hemorrhagic properties; digestive
threats, urogenital and pulmonary infections
[13, 14]; Dysentery, worms, malaria, sexually
transmitted diseases, dental caries and
diarrhea [15].
Tannins, triterpenoids, mucilages
and reducing compounds, flavonoids,
steroids, alkaloids, cardiac glycosides
[10, 14, 48].
Antimicrobial: active against Ca,
Ck, Sa, Sf, Ec, Pa, Sp, Pv, Kp, St, Sd,





roots (17.56 %) and
barks (19.01 %)
Dschang, West region of
Cameroon (6°30′N 10°30′E/
6.500°N 10.500°E)
Malaria, fever, mental illness [50]; venereal
infections and obesity [16, 17] and cancer
[10]
Polysciasoside A, kalopanax-saponin B,
alpha-hederin [51, 52]
Inhibition of microsomal lipid
peroxidation [53]
aPlants were identified at the Cameroon National Herbarium (HNC); ICNA: Voucher with no identification code at the HNC; bThe percentage of the methanol extract; cMicroorganisms[Bs Bacillus subtilis, Ca Candida
albicans, Ck Candida krusei, Mm Mucor miehei, Cv Chlorella vulgaris, Cs Chlorella sorokiniana, Ec Escherichia coli, Esp Enterococcus species, Mtb Mycobacterium tuberculosis, Ms Mycobacterium smegmatis, Ng Neisseria
gonorrhoeae, Pa Pseudomonas aeruginosa, Sf Streptococcus faecalis, Pv Proteus vulgaris, Sa Staphylococcus aureus, Sp Streptococcus pneumoniae, St Salmonella typhimurium, Kp Klepsiella pneumoniae, Sd Shigella


















MBC was regarded as the lowest concentration of ex-
tracts, which did not produce a color change after
addition of INT as mentioned above [21, 22].
Samples were tested alone and the best four extracts
(those from the leaves and bark of Beilschmedia acuta,
and from the leaves of Newbouldia laevis and Polyscias
fulva) were also selected and tested in association with
antibiotics at the sub-inhibitory concentrations (MIC/2
and MIC/5) [7–9] against nine MDR bacteria. Fractional
inhibitory concentration (FIC) was calculated as the
Table 2 Bacterial strains used and their features
Strains Features and References
Escherichia coli
ATCC10536 Reference strain
AG100 Wild-type E. coli K-12 [54]
AG100A AG100 ΔacrAB::KANR [34, 54, 55]
AG100ATET ΔacrAB mutant AG100, with
over-expressing acrF gene; TETR
[54]
AG102 ΔacrAB mutant AG100, owing acrF
gene markedly over-expressed; TETR
[56, 57]
MC4100 Wild type E. coli [58]
W3110 Wild type E. coli [58, 59]
Enterobacter aerogenes
ATCC13048 Reference strains
CM64 CHLR resistant variant obtained from
ATCC13048 over-expressing the AcrAB pump
[60]
EA3 Clinical MDR isolate; CHLR, NORR, OFXR,
SPXR, MOXR, CFTR, ATMR, FEPR
[61, 62]
EA27 Clinical MDR isolate exhibiting energy-dependent
norfloxacin and chloramphenicol efflux with
KANR AMPR NALR STRR TETR
[61, 62]
EA289 KAN sensitive derivative of EA27 [63]
EA294 EA289 acrA::KANR [63]
EA298 EA 289 tolC::KANR [63]
Enterobacter cloacae
ECCI69 Clinical MDR isolates, CHLR [7]
BM67 Clinical MDR isolates, CHLR [7]
Klebsiella pneumoniae
ATCC12296 Reference strains
KP55 Clinical MDR isolate, TETR, AMPR, ATMR, CEFR [64]
KP63 Clinical MDR isolate, TETR, CHLR, AMPR, ATMR [64]
K24 AcrAB-TolC, Laboratory collection of UNR-MD1,
University of Marseille, France
[7]
K2 AcrAB-TolC, Laboratory collection of UNR-MD1,
University of Marseille, France
[7]
Providencia stuartii [65]
NEA16 Clinical MDR isolate, AcrAB-TolC
ATCC29916 Clinical MDR isolate, AcrAB-TolC
PS2636 Clinical MDR isolate, AcrAB-TolC
PS299645 Clinical MDR isolate, AcrAB-TolC
Pseudemonas aeruginosa
PA 01 Reference strains
PA 124 MDR clinical isolate [66]
aAMP, ATMR, CEFR, CFTR, CHLR, FEPR, KANR, MOXR, STRR, TETR. Resistance to ampicillin, aztreonam, cephalothin, cefadroxil, chloramphenicol, cefepime, kanamycin,
moxalactam, streptomycin, and tetracycline; MDR Multidrug resistant
Tankeo et al. BMC Complementary and Alternative Medicine  (2015) 15:412 Page 4 of 10
ratio of MICAntibiotic in combination/MICAntibiotic alone and
the results were discussed as follows: synergy (≤0.5),
indifferent (0.5 to 4), or antagonism (>4) [25, 26]. All
assays were performed in triplicate.
Results
The antibacterial activities of methanol extracts from
various parts of Beilschmedia acuta, Clausena anisata,
Newbouldia laevis and Polyscias fulva are summarized
in Table 3 (MIC values up to 1024 μg/mL are provided
as supporting information; Additional file 1: Table S1). It
can be observed that extracts from the bark of B. acuta
were active on all 26 tested Gram-negative bacteria, with
MICs ranging from values below 8 to 256 μg/mL. Other
samples displayed selective activities, their inhibitory
effects being observed against nine (34.62 %) of the 26
bacterial strains for N. laevis leaves extract, six (23.10 %)
for both C. anisata leaves and roots extracts, seven
(26.9 %) and four (15.4 %) for leaves and roots extracts
of P. fulva respectively. Extract from the bark of B. actua
Table 3 MICs (μg/mL) of the crude extracts and ciprofloxacin on the panel of tested bacteria
Bacterial strains Studied samples and MIC (μg/mL)
Beilschmedia acuta Clausena anisata Newbouldia laevis Polyscias fulva Reference drug
L B F L R L B L B R CIP
Escherichia coli
ATCC 10536 >256 64 >256 256 256 128 >256 >256 >256 >256 1
AG 100A >256 128 >256 >256 >256 256 >256 >256 >256 >256 <0.5
AG 100 >256 16 >256 >256 >256 >256 >256 >256 >256 >256 16
AG 100ATet >256 256 >256 >256 >256 >256 >256 >256 >256 >256 64
AG 102 >256 64 >256 >256 >256 >256 >256 >256 >256 >256 4
MC 4100 256 128 256 256 256 128 >256 256 >256 256 16
W 3110 256 <8 256 256 256 128 >256 128 >256 128 32
Enterobacter aerogenes
ATCC 13048 >256 16 >256 >256 >256 >256 >256 256 >256 >256 32
CM 64 >256 16 >256 >256 >256 >256 >256 >256 >256 >256 64
EA3 >256 64 >256 >256 >256 >256 >256 >256 >256 >256 16
EA27 >256 64 >256 >256 >256 128 >256 256 >256 >256 4
EA 294 >256 64 >256 >256 256 256 >256 >256 >256 >256 2
EA 289 >256 256 256 >256 >256 >256 >256 >256 >256 >256 128
EA 298 >256 256 256 >256 >256 >256 >256 >256 >256 >256 16
Klebsiella pneumoniae
ATCC11296 128 <8 256 256 256 128 >256 128 256 128 <0.5
K2 >256 256 >256 >256 >256 >256 >256 >256 >256 >256 16
KP55 >256 32 >256 >256 >256 >256 >256 >256 >256 >256 4
KP63 128 64 128 256 >256 256 >256 128 >256 128 4
Providencia stuartii
ATCC29916 >256 128 >256 >256 >256 >256 >256 >256 >256 >256 32
PS2636 256 64 256 256 128 128 >256 256 >256 >256 64
PS299645 >256 256 >256 >256 >256 >256 >256 >256 >256 >256 32
NAE16 >256 32 >256 >256 >256 >256 >256 >256 >256 >256 128
Enterobacter cloacae
ECCI69 >256 256 >256 >256 >256 >256 >256 >256 >256 >256 256
BM67 >256 256 >256 >256 >256 >256 >256 >256 >256 >256 32
Pseudomonas aeruginosa
PA01 >256 64 256 >256 >256 >256 >256 >256 >256 >256 16
PA124 >256 32 >256 >256 >256 >256 >256 >256 >256 >256 32
The tested extracts were obtianed from the leaves (L), bark (B), roots (R) or fruits (F); CIP: ciprofloxacin]; MIC and MBC data with values up to 1024 μg/mL are
provided as supporting information (Additional file 1: Table S1)
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Bacterial strainsb, MIC (μg/mL) of antibiotics in the absence and presence of the extract and FIC in
parenthesis
PBSS (%)
AG102 AG100ATET EA27 CM64 KP55 NAE16 BM67 PA01 PA124
CIP 0 4 64 4 64 4 128 32 16 32
L MIC/2 4 (1)I 64 (1)I 1 (0.25)S 64 (1)I 8 (2)A 128 (1)I 16
(0.50)S
16 (1)I 16(0.50)S 3/9
(27.27 %)
MIC/5 4 (1)I 64 (1)I 2 (0.50)S 64 (1)I 8 (2)A 128 (1)I 32 (1)I 16 (1)I 32(1)I 1/9
(11.11 %)
B MIC/2 4 (1)I 32 (0.50)S 1 (0.25)S 64 (1)I 4 (1)I 128 (1)I 16
(0.50)S
16 (1)I 32(1)I 3/9
(27.27 %)
MIC/5 4 (1)I 64 (1)I 2 (0.50)S 64 (1)I 4 (1)I 128 (1)I 32 (1)I 16 (1)I 32(1)I 3/9
(27.27 %)
TET 0 8 64 64 32 2 64 32 64 16
L MIC/2 2 (0.25)S 32 (0.50)S 32
(0.50)S
8 (0.25)S 2 (1)I 32
(0.50)S
32 (1)I 16 (0.25)S 8(0.50)S 7/9
(77.78 %)
MIC/5 4 (0.50)S 64 (1)I 64 (1)I 16 (0.50)S 2 (1)I 64 (1)I 32 (1)I 64 (1)I 8(0.50)S 3/9
(27.27 %)
B MIC/2 4 (0.50)S 32 (0.50)S 16
(0.25)S




32 (0.50)S 8(0.50)S 9/9 (100 %)
MIC/5 4 (0.50)S 64 (1)I 64 (1)I 16 (0.50)S 1 (0.50)S 32
(0.50)S
32 (1)I 64 (1)I 16(1)I 4/9
(36.36 %)
KAN 0 - 16 128 4 16 16 64 4 128
L MIC/2 8(˂0.03)S 4 (0.25)S 64
(0.50)S
2 (0.50)S 16 (1)I 16 (1)I 32
(0.50)S
4 (1)I 64(0.50)S 6/9
(66.67 %)
MIC/5 64 (˂0.25)S 16 (1)I 128 (1) 4 (1)I 16 (1)I 16 (1)I 64 (1)I 2 (0.50)S 64(0.50)S 3/9
(27.27 %)










8 (0.50)S 128 (1)I 2 (0.50)S 4 (0.25)S 16 (1)I 32
(0.50)S
<1 (<0.25)S 64(0.50)S 6/9
(66.67 %)
AMP 0 - - - - - - - - -
L MIC/2 128
(˂0.50)S
128 (˂1)S -(≥1) -(≥1) -(≥1) - (≥1) -(≥1) -(≥1) -(≥1) 2/9
(22.22 %)






-(≥1) 256 (˂1)S -(≥1) 256 (<1)S 256
(<1)S
-(≥1) -(≥1) 256(<1)S 5/9
(55.55 %)
MIC/5 256 (˂1)S -(≥1) -(≥1) -(≥1) -(≥1) - (≥1) -(≥1) 256 (˂1)S -(>1) 2/9
(22.22 %)
CHL 0 32 64 64 - 8 64 128 16 128
L MIC/2 16 (0.50)S 32 (0.50)S 64 (1)I 128
(˂0.50)S
16 (2)A 8 (0.13)S 64
(0.50)S
2 (0.13) 64(0.50)S 6/9
(66.67 %)




8 (0.50)S 128(1)I 3/9
(27.27 %)
B MIC/2 32 (1)I 32 (0.50)S 32
(0.50)S




4 (0.25)S 64(0.50)S 8/9
(88.89 %)
MIC/5 32 (1)I 32 (0.50)S 64 (1)I -(˃1) 2 (0.25)S 32
(0.50)S
128 (1)I 8 (0.50)S 64(0.50)S 5/9
(55.55 %)
aAntibotics [TET tetracycline, CIP ciprofloxacin, KAN kanamycin, CHL chloramphenicol, AMP ampicillin]. bBacterial strains: Escherichia coli [AG102, AG100Atet],
Pseudomonas aeruginosa [PA01, PA124], Enterobacter aerogenes [CM64, EA27], Enterobacter cloacae [BM67], Klebsiella pneumoniae [KP55], Providencia stuartii
[NAE16]. cPBSS: percentage of bacteria strain on which synergism has been observed
(): fold increase in MIC values of the antibiotics after association with plants extract; S synergy, I indifference, na not applicable, B bart extract, L leaves extract, FIC
fractional inhibitory concentration, (−): >256 μg/mL; 0: no extract (only antibiotic tested)
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Bacterial strainsb, MIC (μg/mL) of antibiotics in the absence and presence of the extract and FIC in
parenthesis
PBSS (%)
AG102 AG100ATET EA27 CM64 KP55 NAE16 BM67 PA01 PA124
Newbouldia laevis
CIP 0 4 64 4 64 4 128 32 16 32
MIC/2 4 (1)I 64 (1)I 2
(0.50)S
32 (0.50)S 4 (1)I 128 (1)I 16
(0.50)S
16 (1)I 32(1)I 3/9
(27.27 %)
MIC/5 4 (1)I 64 (1)I 2
(0.50)S
64 (1)I 4 (1)I 128 (1)I 32 (1)I 16 (1)I 32(1)I 1/9
(11.11 %)
TET 0 8 64 64 32 2 64 32 64 16
MIC/2 4 (0.50)S 16 (0.25)S 32
(0.50)S




32 (0.50)S 8(0.50)S 8/9
(88.89 %)
MIC/5 8 (1)I 32 (0.50)S 64 (1)I 8 (0.25)S 0.50 (0.25)S 64 (1)I 32 (1)I 64 (1)I 8(0.50)S 4/9
(36.36 %)
KAN 0 - 16 128 4 16 16 64 4 128
MIC/2 4 (˂0.03)S 8 (0.50)S 64
(0.50)S












4 (1)I 64(0.50)S 5/9
(55.55 %)
AMP 0 - - - - - - - - -




-(≥1) -(≥1) -(>1) 2/9
(22.22 %)
MIC/5 -(≥1) -(≥1) -(≥1) -(≥1) 256 (˂1)S - (≥1) -(≥1) -(≥1) -(>1) 1/9
(11.11 %)
CHL 0 32 64 64 - 8 64 128 16 128






4 (0.25)S 128(1)I 7/9
(77.78 %)






16 (1)I 128(1)I 4/9
(36.36 %)
Polyscias fulva
CIP 0 4 64 4 64 4 128 32 16 32
MIC/2 4 (1)I 64 (1)I 2
(0.50)S
64 (1)I 4 (1)I 128 (1)I 2
(0.06)S
8 (0.50)S 32(1)I 3/9
(27.27 %)
MIC/5 4 (1)I 64 (1)I 2
(0.50)S
64 (1)I 4 (1)I 128 (1)I 4
(0.13)S
16 (1)I 32(1)I 2/9
(22.22 %)
TET 0 8 64 64 32 2 64 32 64 16








2 (0.03)S 8(0.50)S 9/9
(100 %)
MIC/5 4 (0.50)S 64 (1)I 32
(0.50)S
16 (0.50)S 2 (1)I 32
(0.50)S
32 (1)I 32 (0.50)S 8(0.50)S 6/9
(66.67 %)
KAN 0 - 16 128 4 16 16 64 4 128
MIC/2 8(˂0.06)S 8 (0.50)S 64
(0.50)S














4 (1)I 64(0.50)S 4/9
(36.36 %)





-(≥1) 256 (˂1)S 256
(˂1)S
-(≥1) 256 (˂1)S -(>1) 5/9
(55.55 %)
MIC/5 256 (˂1)S -(≥1) -(≥1) -(≥1) -(≥1) -(˃1) -(≥1) -(≥1) -(>1) 1/9
(11.11 %)
CHL 0 32 64 64 - 8 64 128 16 128
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showed the best antibacterial activity with MIC values
below 100 μg/mL against 16/26 (61.5 %) of the tested
microorganisms. The lowest MIC values below 8 μg/mL
were obtained with this extract against Escherichia coli
W3110 and Klebsiella pneumoniae ATCC11296. MIC
values of this extract were lower than those of ciproflox-
acin against E. coli W3110, Enterobacter aerogenes
ATCC13048 and CM64 and Providencia stuartii NAE16
(Table 3). The bactericidal activities of studied samples
were mostly noted with the extract from B. acuta, with
MBC values observed against 23/26 (88.5 %) tested bac-
teria (see Additional file 1: Table S2, supporting
information).
Five commonly used antibiotics (CIP, TET, KAN, AMP
and CHL) were combined with extracts from B. acuta
leaves and bark and those from the leaves of N. laevis
and P. fulva at their MIC/2 and MIC/5, as obtained on
each of nine tested bacterial strains (Tables 4 and 5).
Synergistic effects were observed with all tested extracts
and all studied antibiotics on at least one of the nine
selected bacteria. The best percentages of synergistic
effect (100 %) were obtained at MIC/2 with B. acuta
bark extract in combination with TET (Table 5) as well
as with P. fulva leaves extract in association with TET
and KAN (Table 5).
Discussion
Phytochemicals are routinely classified as antimicrobials
on the basis of susceptibility tests that produce MICs in
the range of 100 to 1000 μg/mL [27]. Moreover, for
crude extracts, the antimicrobial activity is considered to
be significant if MIC values are below 100 μg/mL and
moderate when 100<MIC <625 μg/mL [28, 29]. There-
fore, the activity recorded with B. acuta bark extract
against the 26 tested bacterial strains can be considered
as very important. If we consider the alternative criteria
described by Fabry et al. [30], where extracts having
MIC values less than 8000 μg/mL have noteworthy anti-
microbial activity, the overall activity recorded with the
leaves and fruit extracts of B. acuta, P. fulva and N. lae-
vis leaves extracts can also be considered promising. A
keen look of the results of MIC and MBC determina-
tions (Table 3, Additional file 1: Tables S1 and S2)
indicates that MBC/MIC ratios were mostly above four,
suggesting that studied extracts, including the most ac-
tive ones, generally displayed bacteriostatic effects
(MBC/MIC > 4) [31–33]. Various classes of phytochemi-
cals (Table 2) were previously detected in the extracts of
the four tested plants [10] and this may explain their
antibacterial activity.
The results obtained in this study, and mostly those
obtained with the bark of B. acuta are very important
when taking in consideration the fact that most of the
bacterial strains used were MDR phenotypes expressing
active efflux pumps [7–9, 34, 35]. In fact, the activity of
antibiotics against the studied MDR bacteria was previ-
ously found to increase in the presence of phenylalanine
arginine β-naphthylamide (PAßN), a potent inhibitor
of RND efflux systems, particularly AcrAB–TolC (of
Enterobaceriaceae) and MexAB–OprM (of Pseudo-
monas species) [7–9, 34, 35]. In the present study, we
demonstrated that beneficial effects when combining
four of the tested plant extracts [namely those from B.
acuta (leaves and bark), N. leavis (leaves) and P. fulva
(leaves)] with the first line antibiotics could be
achieved. High percentages of synergistic effects
(100 %) obtained with B. acuta bark extract and TET
as well as P. fulva leaves extract in combination with
TET and KAN, clearly suggest that such associations
could improve the fight against MDR bacterial infec-
tions. This also suggests that some of the constituents
of the corresponding plants can act as efflux pump
inhibitors, as more than 70 % synergistic cases were
observed with many combinations [26].
The antimicrobial potential of the genus Beilschmiedia
has previously been documented. Chouna et al. [36]
demonstrated that compounds such as beilschmiedic
acid C isolated from B. anacardioides were significantly
active against Bacillus subtilis, Micrococcus luteus and
Streptococcus faecalis. Beilschmiedia cinnamomea was
previously reported to have significant to moderate ac-
tivities (64–1024 μg/mL) against the MDRGN tested in
this work [7]. Beilschmedia obscura was also found to
show a good and large spectrum of antibacterial activity
against MDRGN [37]. Some compounds previously iso-
lated from the genus Beilschmiedia and belonging to
Table 5 MIC of antibiotics after the association of the extract of Newbouldia laevis and Polysicas fulva at MIC/2 and MIC/5 against
selected MDR bacteria (Continued)






2 (0.13)S 64(0.50)S 7/9
(77.78 %)




16 (1)I 64(0.50)S 5/9
(55.55 %)
aAntibotics [TET tetracycline, CIP ciprofloxacin, KAN kanamycin, CHL chloramphenicol, AMP ampicillin]. bBacterial strains: Escherichia coli [AG102, AG100Atet],
Pseudomonas aeruginosa [PA01, PA124], Enterobacter aerogenes [CM64, EA27], Enterobacter cloacae [BM67], Klebsiella pneumoniae [KP55], Providencia stuartii
[NAE16]. cPBSS percentage of bacteria strain on which synergism has been observed, NA not applicable
(): fold increase in MIC values of the antibiotics after association with plants extract, S synergy, I indifference, na not applicable, FIC fractional inhibitory
concentration, (−): >256 μg/mL, 0: no extract (only antibiotic tested)
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alkaloids, phenols, saponines, sterols and triterpenoids
[36, 38] were shown to possess antimicrobial activities
[7]. The genus Beilschmiedia is also known traditionally
to possess antimicrobial activities [7]. Beilschmedia
acuta tested in this study is also used in Cameroon to
treat gastrointestinal infections [10]. The obtained data
highlight the importance of this plant in the control of
microbial infections and mostly those involving MDR
phenotypes. The antimicrobial activities of extracts and
compounds from Newbouldia laevis towards sensitive
bacteria and fungi were also reported [39, 40], and the
present study provides additional data on the potential
of this plant to fight MDR bacteria. Also, the antimicro-
bial activity of essential oil from Clausena anisata was
reported against Staphylococcus aureus, Streptococcus
pneumoniae, Enterococcus species, Salmonella typhimur-
ium and Pseudomonas aeruginosa [41, 42]. The present
report provides more evidence of the antimicrobial
potential of this plant.
Conclusion
The results of this study are very interesting, in
regards to the medical importance of the studied
microorganisms. These data provided evidence that
crude extracts from the studied plants and mostly that
from the bark of Beilschmedia acuta are potential
sources of antimicrobial drugs to fight MDR bacterial
infections. The purification of this plant will be carried
out to isolate its active constituents. The cytotoxicity
assays on normal cell lines constitute the limitation of
the present work and will further be performed to
ensure the safety of the tested extracts.
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